Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CFB | P00751 | 4/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928266 | 0.74 | ALDH1A1 (0.47) | ALDH1A1TDP1TSHRSMN1; SMN2MEN1 | |
| SCHEMBL19251836 | 0.74 | TSHR (0.50) | ALDH1A1TDP1TSHRGRIN2DGRIN3B | |
| SCHEMBL18876052 | 0.71 | CFB (0.47) | ALDH1A1CFBKMT2ALMNACYP3A4 | |
| SCHEMBL27933693 | 0.71 | ADORA2A (0.42) | ALDH1A1TDP1TSHRGRIN2DGRIN3B | |
| SCHEMBL2263267 | 0.71 | ALDH1A1 (0.53) | ALDH1A1TDP1TSHRGRIN2DGRIN3B | |
| SCHEMBL1562943 | 0.71 | TSHR (0.59) | ALDH1A1TDP1TSHRSMN1; SMN2MEN1 | |
| SCHEMBL2768608 | 0.70 | ALDH1A1 (0.44) | ALDH1A1TDP1TSHRSMN1; SMN2MEN1 | |
| SCHEMBL29764388 | 0.70 | ALDH1A1 (0.44) | ALDH1A1TDP1TSHRSMN1; SMN2MEN1 | |
| SCHEMBL6537796 | 0.70 | CCR8 (0.53) | ALDH1A1TDP1TSHRGRIN2DGRIN3B | |
| SCHEMBL28420852 | 0.70 | ALDH1A1 (0.54) | ALDH1A1TDP1TSHRGRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10093663-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2018-10-09 | — | — | US | disclosed |
| EP-3299365-A1 | PIPERIDINYL-INDOLE DERIVATIVES COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF | Novartis AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-20180009795-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2018-01-11 | — | — | US | disclosed |
| EP-3022192-B1 | PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS | NOVARTIS AG (CH) | 2017-10-11 | — | — | EP | disclosed |
| EP-3022192-B1 | PIPERIDINYL INDOLE DERIVATIVES AND THEIR USE AS COMPLEMENT FACTOR B INHIBITORS | NOVARTIS AG (CH) | 2017-10-11 | — | — | EP | disclosed |
| US-9682968-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | NOVARTIS AG (CH) | 2017-06-20 | — | — | US | disclosed |
| EP-2855456-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| EP-2855456-B1 | COMPLEMENT PATHWAY MODULATORS AND USES THEREOF | NOVARTIS AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| CN-104603127-B | Complement pathway modulators and uses thereof | 诺华股份有限公司 | 2016-10-05 | — | — | CN | disclosed |
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | NOVARTIS AG (CH) | 2016-06-02 | — | — | US | disclosed |
| CN-105579444-A | Piperidinylindole derivatives and their use as complement factor B inhibitors | NOVARTIS AG | 2016-05-11 | — | — | CN | disclosed |
| US-20150250767-A1 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-09-10 | — | — | US | disclosed |
| US-9056874-B2 | Complement pathway modulators and uses thereof | NOVARTIS AG (CH) | 2015-06-16 | — | — | US | disclosed |
| CN-104603127-A | Complement pathway modulators and uses thereof | NOVARTIS AG | 2015-05-06 | — | — | CN | disclosed |
| WO-2014143638-A1 | 2-(1H-INDOL-4-YLMETHYL)-3H-IMIDAZO[4,5-B]PYRIDINE-6-CARBONITRILE DERIVATIVES AS COMPLEMENT FACTOR B INHIBITORS USEFUL FOR THE TREATMENT OF OPHTHALMIC DISEASES | NOVARTIS AG (CH) | 2014-09-18 | — | — | WO | disclosed |
| US-20130296377-A1 | Complement pathway modulators and uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2013-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152605-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | CFB, TFPI, TFPI2 | ALDH1A1 1827/4885TDP1 4628/4885TSHR 2719/4885 |
| US-10093663-B2 | Piperidinyl-indole derivatives complement factor B inhibitors and uses thereof | CFB, C5, TFPI | ALDH1A1 1590/4885TDP1 4507/4885TSHR 2710/4885 |
| US-20150250767-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | ALDH1A1 2495/4885TDP1 4428/4885TSHR 2475/4885 |
| US-20130296377-A1 | Complement pathway modulators and uses thereof | C5, C3AR1, C9 | ALDH1A1 2495/4885TDP1 4428/4885TSHR 2475/4885 |
| US-20180009795-A1 | Piperidinyl-Indole Derivatives Complement Factor B Inhibitors and Uses Thereof | CFB, C5, TFPI | ALDH1A1 1590/4885TDP1 4507/4885TSHR 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.